Document Detail


Clopidogrel and aspirin versus clopidogrel alone on graft patency after coronary artery bypass grafting.
MedLine Citation:
PMID:  19559191     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Clopidogrel and aspirin are the most popular antiplatelet agents for anticoagulation management after coronary artery bypass grafting (CABG) in clinical practice, but there is neither a standard antiplatelet therapy for patients undergoing CABG, nor an exact conclusion about its effects on graft patency until now. METHODS: One-hundred and ninety-seven selected patients undergoing CABG were assigned to two groups according to antiplatelet drug: the clopidogrel group of 102 patients who received clopidogrel (75 mg) daily; and the combination group of 95 patients who received clopidogrel (75 mg) plus aspirin (100 mg) daily. Multislice computed tomography angiography was performed to evaluate graft patency at 1 month and 12 months after CABG. RESULTS: There were no significant differences between the two groups in preoperational data. At 1 month and 12 months after CABG graft patency rates of clopidogrel group were, respectively, 99.0% and 96.9% for the left internal mammary artery (LIMA) and 98.1% and 93.5% for the saphenous vein grafts; those of the combination group were, respectively, 98.9% and 97.8% for LIMA, and 98.2% and 96.3% for saphenous vein grafts. There were no significant differences in graft patency between the two groups (p > 0.05). CONCLUSIONS: Either clopidogrel plus aspirin or clopidogrel alone maintain high graft patency in the early postoperative phase after CABG. The observed trend toward higher patency rates in patients treated with clopidogrel plus aspirin compared to those in the clopidogrel group did not reach statistical significance.
Authors:
Changqing Gao; Chonglei Ren; Dong Li; Libing Li
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  88     ISSN:  1552-6259     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-29     Completed Date:  2009-08-05     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  59-62     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiovascular Surgery, PLA General Hospital, PLA Institute of Cardiac Surgery, Beijing, China. gaochq301@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aspirin / therapeutic use*
Coronary Angiography / methods
Coronary Artery Bypass / adverse effects,  methods*
Coronary Stenosis / mortality,  radiography,  surgery
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
Graft Occlusion, Vascular / drug therapy*,  prevention & control,  radiography
Graft Rejection
Graft Survival
Humans
Male
Middle Aged
Platelet Aggregation Inhibitors / therapeutic use
Postoperative Complications / prevention & control
Probability
Prognosis
Surgical Procedures, Elective
Survival Rate
Ticlopidine / analogs & derivatives*,  therapeutic use
Treatment Outcome
Vascular Patency / drug effects*
Chemical
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel
Comments/Corrections
Comment In:
Ann Thorac Surg. 2009 Jul;88(1):62-3   [PMID:  19559192 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Remodeling of reconstructed left anterior descending coronary arteries with internal thoracic artery...
Next Document:  Survival of cardiorespiratory arrest after coronary artery bypass grafting or aortic valve surgery.